{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:10:26Z","timestamp":1790493026220,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Heterologous prime-boost vaccination with viral vectors simian adenovirus 63 (ChAd63) and Modified Vaccinia Ankara (MVA) induces potent T cell and antibody responses in humans. The 8-week regimen demonstrates significant efficacy against malaria when expressing the pre-erythrocytic malaria antigen Thrombospondin-Related Adhesion Protein fused to a multiple epitope string (ME-TRAP). We tested these vaccines in 7 new 4- and 8- week interval schedules to evaluate safety and immunogenicity of multiple ChAd63 ME-TRAP priming vaccinations (denoted A), multiple MVA ME-TRAP boosts (denoted M) and alternating vectors. All regimens exhibited acceptable reactogenicity and CD8<jats:sup>+<\/jats:sup> T cell immunogenicity was enhanced with a 4-week interval (AM) and with incorporation of additional ChAd63 ME-TRAP vaccination at 4- or 8-weeks (AAM or A_A_M). Induction of TRAP antibodies was comparable between schedules. T cell immunity against the ChAd63 hexon did not affect T cell responses to the vaccine insert, however pre-vaccination ChAd63-specific T cells correlated with reduced TRAP antibodies. Vaccine-induced antibodies against MVA did not affect TRAP antibody induction, and correlated positively with ME-TRAP-specific T cells. This study identifies potentially more effective immunisation regimens to assess in Phase IIa trials and demonstrates a degree of flexibility with the timing of vectored vaccine administration, aiding incorporation into existing vaccination programmes.<\/jats:p>","DOI":"10.1038\/s41598-018-21630-4","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T13:55:27Z","timestamp":1518702927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-1016","authenticated-orcid":false,"given":"Carly M.","family":"Bliss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2058-4045","authenticated-orcid":false,"given":"Georgina","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Havelock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Snudden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huw","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone C.","family":"de Cassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Grobbelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Venkatraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Poulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja B.","family":"Mange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul N.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Colloca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9750","authenticated-orcid":false,"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-9629","authenticated-orcid":false,"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-9836","authenticated-orcid":false,"given":"Katie J.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"21630_CR1","unstructured":"WHO. World Malaria Report 2016. (World Health Organisation, Geneva, 2016)."},{"key":"21630_CR2","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1086\/646613","volume":"200","author":"CV Plowe","year":"2009","unstructured":"Plowe, C. V., Alonso, P. & Hoffman, S. L. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis 200, 1646\u20131649, https:\/\/doi.org\/10.1086\/646613 (2009).","journal-title":"J Infect Dis"},{"key":"21630_CR3","first-page":"535","volume":"65","author":"DA Henderson","year":"1987","unstructured":"Henderson, D. A. Principles and lessons from the smallpox eradication programme. Bull World Health Organ 65, 535\u2013546 (1987).","journal-title":"Bull World Health Organ"},{"key":"21630_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1586\/14760584.8.1.5","volume":"8","author":"J John","year":"2009","unstructured":"John, J. Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines 8, 5\u20138, https:\/\/doi.org\/10.1586\/14760584.8.1.5 (2009).","journal-title":"Expert Rev Vaccines"},{"key":"21630_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.0105-2896.2006.00402.x","volume":"211","author":"RM Zinkernagel","year":"2006","unstructured":"Zinkernagel, R. M. & Hengartner, H. Protective \u2018immunity\u2019 by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called \u2018immunological memory\u2019. Immunol Rev 211, 310\u2013319, https:\/\/doi.org\/10.1111\/j.0105-2896.2006.00402.x (2006).","journal-title":"Immunol Rev"},{"key":"21630_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1084\/jem.76.5.477","volume":"76","author":"PF Russell","year":"1942","unstructured":"Russell, P. F. & Mohan, B. N. The Immunization of Fowls against Mosquito-Borne Plasmodium Gallinaceum by Injections of Serum and of Inactivated Homologous Sporozoites. J Exp Med 76, 477\u2013495 (1942).","journal-title":"J Exp Med"},{"key":"21630_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/330664a0","volume":"330","author":"L Schofield","year":"1987","unstructured":"Schofield, L. et al. Gamma interferon, CD8+\u2009T cells and antibodies required for immunity to malaria sporozoites. Nature 330, 664\u2013666, https:\/\/doi.org\/10.1038\/330664a0 (1987).","journal-title":"Nature"},{"key":"21630_CR8","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1016\/j.vaccine.2015.09.094","volume":"33","author":"KJ Ewer","year":"2015","unstructured":"Ewer, K. J. et al. Progress with viral vectored malaria vaccines: A multi-stage approach involving \u201cunnatural immunity\u201d. Vaccine 33, 7444\u20137451, https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.094 (2015).","journal-title":"Vaccine"},{"key":"21630_CR9","doi-asserted-by":"publisher","unstructured":"Hill, A. V. et al. Prime-boost vectored malaria vaccines: Progress and prospects. Hum Vaccin 6, https:\/\/doi.org\/10.4161\/hv.6.1.10116 (2010).","DOI":"10.4161\/hv.6.1.10116"},{"key":"21630_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/infdis\/jir850","volume":"205","author":"GA O\u2019Hara","year":"2012","unstructured":"O\u2019Hara, G. A. et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. The Journal of infectious diseases 205, 772\u2013781, https:\/\/doi.org\/10.1093\/infdis\/jir850 (2012).","journal-title":"The Journal of infectious diseases"},{"key":"21630_CR11","doi-asserted-by":"publisher","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","volume":"4","author":"E Barnes","year":"2012","unstructured":"Barnes, E. et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4, 115ra111, https:\/\/doi.org\/10.1126\/scitranslmed.3003155 (2012).","journal-title":"Sci Transl Med"},{"key":"21630_CR12","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1038\/mt.2012.223","volume":"20","author":"SH Sheehy","year":"2012","unstructured":"Sheehy, S. H. et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 20, 2355\u20132368, https:\/\/doi.org\/10.1038\/mt.2012.223 (2012).","journal-title":"Mol Ther"},{"key":"21630_CR13","doi-asserted-by":"publisher","first-page":"115ra112","DOI":"10.1126\/scitranslmed.3002925","volume":"4","author":"S Colloca","year":"2012","unstructured":"Colloca, S. et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4, 115ra112, https:\/\/doi.org\/10.1126\/scitranslmed.3002925 (2012).","journal-title":"Sci Transl Med"},{"key":"21630_CR14","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1016\/j.vaccine.2009.03.080","volume":"27","author":"M Dudareva","year":"2009","unstructured":"Dudareva, M. et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27, 3501\u20133504, https:\/\/doi.org\/10.1016\/j.vaccine.2009.03.080 (2009).","journal-title":"Vaccine"},{"key":"21630_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ni762","volume":"3","author":"CC Norbury","year":"2002","unstructured":"Norbury, C. C., Malide, D., Gibbs, J. S., Bennink, J. R. & Yewdell, J. W. Visualizing priming of virus-specific CD8+\u2009T cells by infected dendritic cells in vivo. Nat Immunol 3, 265\u2013271, https:\/\/doi.org\/10.1038\/ni762 (2002).","journal-title":"Nat Immunol"},{"key":"21630_CR16","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.4049\/jimmunol.1100302","volume":"187","author":"A Reyes-Sandoval","year":"2011","unstructured":"Reyes-Sandoval, A. et al. CD8+\u2009T effector memory cells protect against liver-stage malaria. Journal of immunology 187, 1347\u20131357, https:\/\/doi.org\/10.4049\/jimmunol.1100302 (2011).","journal-title":"Journal of immunology"},{"key":"21630_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nm0498-397","volume":"4","author":"J Schneider","year":"1998","unstructured":"Schneider, J. et al. Enhanced immunogenicity for CD8+\u2009T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature medicine 4, 397\u2013402 (1998).","journal-title":"Nature medicine"},{"key":"21630_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/nbt1197-1280","volume":"15","author":"SC Gilbert","year":"1997","unstructured":"Gilbert, S. C. et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 15, 1280\u20131284, https:\/\/doi.org\/10.1038\/nbt1197-1280 (1997).","journal-title":"Nat Biotechnol"},{"key":"21630_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nm881","volume":"9","author":"SJ McConkey","year":"2003","unstructured":"McConkey, S. J. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature medicine 9, 729\u2013735, https:\/\/doi.org\/10.1038\/nm881 (2003).","journal-title":"Nature medicine"},{"key":"21630_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3836","volume":"4","author":"KJ Ewer","year":"2013","unstructured":"Ewer, K. J. et al. Protective CD8+\u2009T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4, 2836, https:\/\/doi.org\/10.1038\/ncomms3836 (2013).","journal-title":"Nat Commun"},{"key":"21630_CR21","doi-asserted-by":"publisher","first-page":"286re285","DOI":"10.1126\/scitranslmed.aaa2373","volume":"7","author":"C Ogwang","year":"2015","unstructured":"Ogwang, C. et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med 7, 286re285, https:\/\/doi.org\/10.1126\/scitranslmed.aaa2373 (2015).","journal-title":"Sci Transl Med"},{"key":"21630_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.4049\/jimmunol.177.2.831","volume":"177","author":"D Masopust","year":"2006","unstructured":"Masopust, D., Ha, S. J., Vezys, V. & Ahmed, R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol 177, 831\u2013839 (2006).","journal-title":"J Immunol"},{"key":"21630_CR23","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1038\/mt.2014.109","volume":"22","author":"D Kimani","year":"2014","unstructured":"Kimani, D. et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol Ther 22, 1992\u20132003, https:\/\/doi.org\/10.1038\/mt.2014.109 (2014).","journal-title":"Mol Ther"},{"key":"21630_CR24","doi-asserted-by":"publisher","first-page":"7392","DOI":"10.1128\/JVI.78.14.7392-7399.2004","volume":"78","author":"A Reyes-Sandoval","year":"2004","unstructured":"Reyes-Sandoval, A. et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. Journal of virology 78, 7392\u20137399, https:\/\/doi.org\/10.1128\/JVI.78.14.7392-7399.2004 (2004).","journal-title":"Journal of virology"},{"key":"21630_CR25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.vaccine.2010.10.041","volume":"29","author":"S Capone","year":"2010","unstructured":"Capone, S. et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29, 256\u2013265, https:\/\/doi.org\/10.1016\/j.vaccine.2010.10.041 (2010).","journal-title":"Vaccine"},{"key":"21630_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.vaccine.2011.11.021","volume":"30","author":"G Hermanson","year":"2012","unstructured":"Hermanson, G. et al. Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax((R)) using proteome microarrays and development of recombinant protein ELISAs. Vaccine 30, 614\u2013625, https:\/\/doi.org\/10.1016\/j.vaccine.2011.11.021 (2012).","journal-title":"Vaccine"},{"key":"21630_CR27","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1038\/mt.2011.176","volume":"19","author":"SH Sheehy","year":"2011","unstructured":"Sheehy, S. H. et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19, 2269\u20132276, https:\/\/doi.org\/10.1038\/mt.2011.176 (2011).","journal-title":"Mol Ther"},{"key":"21630_CR28","doi-asserted-by":"publisher","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","volume":"7","author":"SH Sheehy","year":"2012","unstructured":"Sheehy, S. H. et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 7, e31208, https:\/\/doi.org\/10.1371\/journal.pone.0031208 (2012).","journal-title":"PLoS One"},{"key":"21630_CR29","doi-asserted-by":"publisher","first-page":"e57726","DOI":"10.1371\/journal.pone.0057726","volume":"8","author":"C Ogwang","year":"2013","unstructured":"Ogwang, C. et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One 8, e57726, https:\/\/doi.org\/10.1371\/journal.pone.0057726 (2013).","journal-title":"PLoS One"},{"key":"21630_CR30","doi-asserted-by":"publisher","unstructured":"Rampling, T. et al. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S\/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP. J Infect Dis, https:\/\/doi.org\/10.1093\/infdis\/jiw244 (2016).","DOI":"10.1093\/infdis\/jiw244"},{"key":"21630_CR31","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K Ewer","year":"2016","unstructured":"Ewer, K. et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med 374, 1635\u20131646, https:\/\/doi.org\/10.1056\/NEJMoa1411627 (2016).","journal-title":"N Engl J Med"},{"key":"21630_CR32","doi-asserted-by":"crossref","unstructured":"Betts, M. R. et al. Sensitive and viable identification of antigen-specific CD8+\u2009T cells by a flow cytometric assay for degranulation. J Immunol Methods 281, 65\u201378, S0022175903002655 [pii] (2003).","DOI":"10.1016\/S0022-1759(03)00265-5"},{"key":"21630_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/341323a0","volume":"341","author":"P Romero","year":"1989","unstructured":"Romero, P. et al. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341, 323\u2013326, https:\/\/doi.org\/10.1038\/341323a0 (1989).","journal-title":"Nature"},{"key":"21630_CR34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1073\/pnas.85.2.573","volume":"85","author":"WR Weiss","year":"1988","unstructured":"Weiss, W. R., Sedegah, M., Beaudoin, R. L., Miller, L. H. & Good, M. F. CD8+\u2009T cells (cytotoxic\/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85, 573\u2013576 (1988).","journal-title":"Proc Natl Acad Sci USA"},{"key":"21630_CR35","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1084\/jem.182.5.1435","volume":"182","author":"B Wizel","year":"1995","unstructured":"Wizel, B. et al. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med 182, 1435\u20131445 (1995).","journal-title":"J Exp Med"},{"key":"21630_CR36","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1128\/IAI.72.5.2598-2604.2004","volume":"72","author":"S Nookala","year":"2004","unstructured":"Nookala, S., Srinivasan, S., Kaliraj, P., Narayanan, R. B. & Nutman, T. B. Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis. Infect Immun 72, 2598\u20132604 (2004).","journal-title":"Infect Immun"},{"key":"21630_CR37","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1086\/515661","volume":"178","author":"PJ Cooper","year":"1998","unstructured":"Cooper, P. J., Espinel, I., Paredes, W., Guderian, R. H. & Nutman, T. B. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10. J Infect Dis 178, 1133\u20131138 (1998).","journal-title":"J Infect Dis"},{"key":"21630_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1471-4922(01)02117-1","volume":"17","author":"M Nacher","year":"2001","unstructured":"Nacher, M. Malaria vaccine trials in a wormy world. Trends Parasitol 17, 563\u2013565 (2001).","journal-title":"Trends Parasitol"},{"key":"21630_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/infdis\/jis404","volume":"206","author":"J Yin","year":"2012","unstructured":"Yin, J. et al. Plasmodium inui infection reduces the efficacy of a simian immunodeficiency virus DNA vaccine in a rhesus macaque model through alteration of the vaccine-induced immune response. J Infect Dis 206, 523\u2013533, https:\/\/doi.org\/10.1093\/infdis\/jis404 (2012).","journal-title":"J Infect Dis"},{"key":"21630_CR40","doi-asserted-by":"publisher","first-page":"10028","DOI":"10.1128\/JVI.01015-09","volume":"83","author":"ER Manuel","year":"2009","unstructured":"Manuel, E. R. et al. Dominant CD8+\u2009T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus. J Virol 83, 10028\u201310035, https:\/\/doi.org\/10.1128\/JVI.01015-09 (2009).","journal-title":"J Virol"},{"key":"21630_CR41","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","volume":"211","author":"SH Hodgson","year":"2015","unstructured":"Hodgson, S. H. et al. Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. J Infect Dis 211, 1076\u20131086, https:\/\/doi.org\/10.1093\/infdis\/jiu579 (2015).","journal-title":"J Infect Dis"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21630-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:39:56Z","timestamp":1671590396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21630-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["21630"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-21630-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,21]]},"assertion":[{"value":"14 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Adrian Hill and Sarah Gilbert are named inventors on patent applications and patents relating to malaria vectored vaccines and immunization regimens. Stefano Colloca and Alfredo Nicosia are employees of and\/or shareholders in ReiThera, which is developing vectored vaccines for malaria and other diseases.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3390"}}